MediWound's EscharEx Phase III study cleared to continue by safety board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to MediWound's EscharEx Phase III study cleared to continue by safety board

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

September 14, 2026 7:00 AM EDT

Independent DSMB Recommends MediWounds EscharEx® Phase III VALUE Study Continue Without Modification

DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027

YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase... More